Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor

Journal of Thrombosis and Thrombolysis

Volumn 31, Issue 4, 2011, Pages 478-492

  Wong, Pancras C ^a   Pinto, Donald J P ^a   Zhang, Donglu ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Anticoagulants; Atrial fibrillation; Factor Xa; Keywords apixaban; Thrombosis

Indexed keywords

3 HYDROXY APIXABAN; ACETYLSALICYLIC ACID; APIXABAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; BREAST CANCER RESISTANCE PROTEIN; CLOPIDOGREL; CYTOCHROME P450 3A4; DABIGATRAN; ENOXAPARIN; GLYCOPROTEIN P; HEPARIN; KETOCONAZOLE; O DEMETHYL APIXABAN; O DEMETHYL APIXABAN SULFATE; PLACEBO; PROTEINASE; RIVAROXABAN; THROMBIN; UNCLASSIFIED DRUG; WARFARIN; ENZYME INHIBITOR; FIBRINOLYTIC AGENT; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; AREA UNDER THE CURVE; ARTERY THROMBOSIS; ARTICLE; BILIARY EXCRETION; BLEEDING TIME; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; HEART ATRIUM FIBRILLATION; HEMOSTASIS; HUMAN; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RABBIT; STRUCTURE ANALYSIS; THROMBOCYTE AGGREGATION INHIBITION; THROMBOEMBOLISM; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY EXCRETION; VENOUS THROMBOEMBOLISM; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; DRUG DEVELOPMENT; HISTORY; REVIEW;

ANIMALS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; FACTOR XA; FIBRINOLYTIC AGENTS; HISTORY, 20TH CENTURY; HUMANS; PYRAZOLES; PYRIDONES; THROMBOEMBOLISM;

EID: 80052351015     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-011-0551-3     Document Type: Article

References (57)

1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G et al (2010) American Heart Association Statistics Committee and Stroke Statistics Committee. Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 121:948-954
2. Ruppert A, Lees M, Steinle T (2010) Clinical burden of venous thromboembolism. Curr Med Res Opin 26:2465-2473
3. Mann KG, Butenas S, Brummel K (2003) The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol 23:17-25 (Pubitemid 36091621)
4. McKenzie CR, Abendschein DR, Eisenberg PR (1996) Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated factor Xa. Arterioscler Thromb Vasc Biol 16:1285-1291 (Pubitemid 26339717)
5. Harker LA, Hanson SR, Kelly AB (1995) Antithrombotic benefits and hemorrhagic risks of direct thrombin antagonists. Thromb Haemost 74:464-472
6. Wong PC, Crain EJ, Watson CA, Zaspel AM, Wright MR, Lam PY et al (2002) Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits. J Pharmacol Exp Ther 303: 993-1000 (Pubitemid 35424381)
7. Wong PC, Crain EJ, Watson CA, Xin B (2009) Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits. J Thromb Haemost 7:1313-1320
8. Hauptmann J, Sturzebecher J (1999) Synthetic inhibitors of thrombin and factor Xa: from bench to bedside. Thromb Res 93:203-241 (Pubitemid 29130456)
9. Leadley RJ Jr (2001) Coagulation factor Xa inhibition: biological background and rationale. Curr Top Med Chem 1:151-159
10. Turpie AG (2004) Fondaparinux: a factor Xa inhibitor for antithrombotic therapy. Expert Opin Pharmacother 5:1373-1384 (Pubitemid 38885795)
11. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133(6 Suppl): 160S-198S (Pubitemid 351892967)
12. FDANews Release,Oct 19, 2010. FDAapproves Pradaxa to prevent stroke in people with atrial fibrillation [online]. http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm230241.htm. Accessed 22 Dec 2010
13. Pinto DJ, Orwat MJ, Koch S, Rossi KA, Alexander RS, Smallwood A et al (2007) Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)- 4,5,6,7-tetrah ydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 50:5339-5356 (Pubitemid 350057846)
14. Pinto DJ, Smallheer JM, Cheney DL, Knabb RM, Wexler RR (2010) Factor Xa inhibitors: next-generation antithrombotic agents. J Med Chem 53:6243-6274
15. Wong PC, Crain EJ, Xin B, Wexler RR, Lam PY, Pinto DJ et al (2008) Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 6:820-829 (Pubitemid 351524543)
16. APPRAISE Steering Committee and Investigators, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M et al (2009) Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 119:2877-2885
17. Botticelli Investigators Writing Committee, Buller H, Deitchman D, Prins M, Segers A (2008) Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 6:1313-1318 (Pubitemid 352016310)
18. Connolly S, Eikelboom J, Flaker G, Kaatz S, Avezum A, Piegas L et al AVERROES: apixaban versus acetylsalicylic acid (ASA) to prevent strokes. ESC 2010 congress reports. European Society of Cardiology web site. http://www.escardio.org/congresses/esc-2010/congress-reports/Pages/ 708-3-AVERROES.aspx#presenter.Accessed 6 Sept 2010
19. Frost C, Yu Z, Moore K, Nepal S, Barrett Y, Mosqueda-Garcia R et al (2007) Apixaban, an oral direct factor Xa inhibitor: multipledose safety, pharmacokinetics, and pharmacodynamics in healthy subjects. J Thromb Haemost 5(Suppl 2). Abstract PM664
20. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D (2007) The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 5:2368-2375 (Pubitemid 350154345)
21. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ et al (2009) Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 361:594-604
22. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P et al (2010) Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised doubleblind trial. Lancet 375:807-815
23. Quan ML, Pruitt JR, Ellis CD, Liauw AY, Galemmo RA Jr, Stouten PFW et al (1997) Bisbenzamidine isoxazoline derivatives as factor Xa inhibitors. Bioorg Med Chem Lett 7:2813-2818 (Pubitemid 27472834)
24. Quan ML, Ellis CD, Liauw AY, Alexander RS, Knabb RM, Lam G et al (1999) Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2. J Med Chem 42:2760-2773 (Pubitemid 29370422)
25. Quan ML, Liauw AY, Ellis CD, Pruitt JR, Carini DJ, Bostrom LL et al (1999) Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 1. J Med Chem 42:2752-2759 (Pubitemid 29370421)
26. Wong PC, Quan ML, Crain EJ, Watson CA, Wexler RR, Knabb RM (2000) Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics. J Pharmacol Exp Ther 292:351-357 (Pubitemid 30026393)
27. Pruitt JR, Pinto DJ, Estrella MJ, Bostrom LL, Knabb RM, Wong PC et al (2000) Isoxazolines and isoxazoles as factor Xa inhibitors. Bioorg Med Chem Lett 10:685-689 (Pubitemid 30215863)
28. Pinto DJ, Orwat MJ, Wang S, Fevig JM, Quan ML, Amparo E et al (2001) Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-20-(methylsulfonyl)-[1,10- biphenyl]-4-yl]-3-(trifluoromethyl)-1Hpyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 44:566-578 (Pubitemid 32156098)
29. Wong PC, Pinto DJ, Knabb RM (2002) Nonpeptide factor Xa inhibitors: DPC423, a highly potent and orally bioavailable pyrazole antithrombotic agent. Cardiovasc Drug Rev 20:137-152
30. Barrett JS, Davidson AF, Jiao QT, Masqueda-Garcia R, Kornhauser DM, Gangrade NK et al (2001) The effect of food, formulation, and dosing duration on the pharmacokinetics of DPC-423, a potent factor Xa inhibitor (abstract). J Clin Pharmacol 41:1023
31. Quan ML, Lam PY, Han Q, Pinto DJ, He MY, Li R et al (2005) Discovery of 1-(30-aminobenzisoxazol-50-yl)-3-trifluoromethyl-N-[2-fluoro-4-[(20- dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor. J Med Chem 48:1729-1744 (Pubitemid 40396307)
32. Wong PC, Crain EJ, Watson CA, Wexler RR, Lam PY, Quan ML et al (2007) Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits. J Thromb Thrombolysis 24:43-51 (Pubitemid 46831563)
33. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D (2003) A phase II randomized, double-blind, five-arm, parallelgroup, dose-response study of a new oral directly-acting factor Xa inhibitor, razaxaban, for the prevention of deep vein thrombosis in knee replacement surgery-on behalf of the razaxaban investigators. Blood (ASH Annual Meeting Abstracts) 102:111. Abstract 41
34. Pinto DJ, Orwat MJ, Quan ML, Han Q, Galemmo RA Jr, Amparo E et al (2006) 1-[3-Aminobenzisoxazol-50-yl]-3-trifluoromethyl-6-[20-(3-(R)-hydroxy-N-pyr rolidinyl)methyl-[1,10]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-py ridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. Bioorg Med Chem Lett 16:4141-4147 (Pubitemid 43903191)
35. Luettgen JM, Knabb RM, He K, Pinto DJ, Rendina AR (2011) Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma. J Enzyme Inhib Med Chem. Posted online on 20 Dec 2010. doi:10.3109/14756366.2010.535793
36. Krishnaswamy S (2005) Exosite-driven substrate specificity and function in coagulation. J Thromb Haemost 3:54-67 (Pubitemid 41647115)
37. Jiang X, Crain EJ, Luettgen JM, Schumacher WA, Wong PC (2009) Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro. Thromb Haemost 101:780-782
38. Hara T, Yokoyama A, Morishima Y, Kunitada S (1995) Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor. Thromb Res 80:99-104
39. Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH et al (2005) In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct factor Xa inhibitor. J Thromb Haemost 3:514-521 (Pubitemid 41632877)
40. Luettgen J, Wang Z, Seiffert D, Rendina A, Knabb R, Ogletree M (2007) Inhibition of measured thrombin generation in human plasma by apixaban: a predictive mathematical model based on experimentally determined rate constants. J Thromb Haemost 5(Suppl 2). Abstract PT633
41. Wong PC, Jiang X (2010) Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin. Thromb Haemost 104:302-310
42. Schumacher WA, Bostwick JS, Stewart AB, Steinbacher TE, Xin B, Wong PC (2010) Effect of the direct factor Xa inhibitor apixaban in rat models of thrombosis and hemostasis. J Cardiovasc Pharmacol 55:609-616
43. Wong PC, Crain EJ, Watson CA, Hua J, Schumacher WA, Rehfuss R (2009) Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability. Thromb Haemost 101:108-115
44. Wong PC, Watson CA, Crain EJ (2008) Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits. J Thromb Haemost 6:1736-1741
45. Bristol Myers Squibb Press Releases, Nov 18, 2010. APPRAISE-2 study with investigational compound apixaban in acute coronary syndrome discontinued [online]. http://www.bms.com/news/press-releases/pages/default.aspx?RSSLink= http://www.businesswire.com/news/bms/20101118007161/en&t=634266370298980311. Accessed 29 Nov 2010
46. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM, ADVANCE-3 Investigators (2010) Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 363(26):2487-2498
47. Barrett YC, Wang Z, Frost C, Shenker A (2010) Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 104:1263-1271
48. He K, He B, Grace JE, Xin B, Zhang D, Pinto D et al (2006) Preclinical pharmacokinetics and metabolism of apixaban, a potent and selective factor Xa inhibitor. Blood (ASH Annual Meeting Abstracts) 108. Abstract 910
49. Frost C, Yu Z, Nepal S, Bragat A, Moore K, Shenker A et al (2008) Apixaban, a direct factor Xa inhibitor: single-dose pharmacokinetics and pharmacodynamics of an intravenous formulation. J Clin Pharmacol 48:1132. Abstract 142
50. Vakkalagadda B, Frost C, Wang J, Nepal S, Schuster A, Zhang D et al (2009) Effect of rifampin on the pharmacokinetics of apixaban, an oral direct inhibitor of factor Xa. J Clin Pharamcol 49:1124. Abstract 143
51. Zhang D, He K, Raghavan N, Wang L, Crain EJ, He B et al (2010) Metabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits. J Thromb Thrombolysis 29:70-80
52. Frost C, Yu Z, Nepal S, Mosqueda-Garcia R, Shenker A (2007) Apixaban, an oral direct, factor Xa inhibitor: single-dose safety, pharmacokinetics and pharmacodynamics in healthy subjects. J Thromb Haemost 5(Suppl 2). Abstract P-M-665
53. Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG et al (2009) Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 37(1):74-81
54. Wang L, Raghavan N, He K, Luettgen JM, Humphreys WG, Knabb RM et al (2009) Sulfation of o-demethyl apixaban: enzyme identification and species comparison. Drug Metab Dispos 37:802-808
55. Zhang D, He K, Raghavan N, Wang L, Mitroka J, Maxwell BD et al (2009) Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans. Drug Metab Dispos 37:1738-1748
56. Wang L, Zhang D, Raghavan N, Yao M, Ma L, Frost CE et al (2010) In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos 38:448-458
57. Frost C, Wang J, Nepal S, Schuster A, Zhang D, Yu Z et al (2009) Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. J Clin Pharmacol 49:1123. Abstract 139